spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Nemeras preservative-free multidose eye dropper Novelia® approved for Santens Cosopt® for Glaucoma treatments in 29 European countries

Nemera

Santen announced that the preservative free formulation Cosopt iMulti® will launch in 29 European countries in the coming months

Nemera is pleased to announce that its multidose eye dropper Novelia® has been approved for the preservative-free formulation Cosopt iMulti® (20mg/ml dorzolamide + 5mg/ml timolol eye drops, solution).

The granting of licences by the relevant national European competent authorities represents an innovation in glaucoma management, providing preservative-free medicines in multi-dose bottles to allow for effective and convenient, 24-hour intraocular pressure (IOP) control to glaucoma patients aged 18 or over (1).

The European Medicines Agency (EMA) outlines that preservatives should be avoided in patients who are on long-term treatment, or do not tolerate preserved eye drops (2). Switching from preserved to preservative-free topical ocular medications can diminish the harmful effects caused by preservatives (3). For example, switching to Cosopt® preservative-free improved local ocular tolerability for 85% of patients compared with their previous preserved medication (4).

Cosopt® is indicated in the treatment of elevated IOP in patients with open-angle glaucoma or pseudoexfoliative glaucoma when topical beta-blocker monotherapy is not sufficient (1). European local market launches of the new preservative-free multi-dose formulations are expected throughout 2019, under the following names:

The new preservative-free multi-dose formulations have already been launched in some European local markets under the following names:

United Kingdom COSOPT iMulti
Denmark COSOPT sine ukonserveret
Finland, Germany, Iceland, Norway, Sweden COSOPT sine

Some more launches are expected throughout 2019 in the following countries:

Austria, Bulgaria, Croatia, Cyprus, Greece, Portugal, Spain COSOPT iMulti
Belgium, Luxembourg COSOPT Sine Conservans
Czech Republic COSOPT Multi Dose bez konzervačních přísad
Estonia, France COSOPT sine
Hungary COSOPT Multi
Ireland COSOPT Multi Preservative Free
Italy COSOPT
Latvia, Lithuania COSOPT PF
Poland COSOPT PF Multi
Romania COSOPT fara conservant
Slovak Republic COSOPT Multi Dose Free
Slovenia COSOPT brez konzervansa
The Netherlands COSOPT Multidose conserveermiddelvrij

The preservative-free multi-dose bottles for Cosopt®, developed by Nemera, feature a low squeeze force and smooth bottle, to reduce the pressure required to dispense a drop and improve ease-of-use, particularly for the elderly (5,6).

"We are delighted to launch preservative-free multi-dose formulations of these glaucoma therapies in Europe,” said Luis Iglesias, Corporate Officer and Head of EMEA, Santen. “By providing highly effective and well-tolerated, preservative-free medicines, with the option for multi-dose bottles, we hope to empower patients in their daily lives and improve the management of their condition.”

“Patient adherence is the key for success for all treatments, especially silent chronic ophthalmic diseases. This is why, at Nemera, we developed an innovative system combining all patient needs: a safe preservative-free multi-dose bottle with a blue tip that makes consistent drops one by one” commented Fanny Sellier, Global Category Manager for Ophthalmic Products, Nemera.

Novelia® is a multidose closing tip system which avoids the need for preservatives in the drug and prevents bacterial contamination over the duration of treatment.

It limits the distribution of liquid to one drop at a time, with a precise and consistent drop size, to improve patients’ adherence.

Key benefits of Novelia®

• 100% controlled and safe thanks to its patented PureFlow® Technology
• Works with high viscosity suspensions, emulsions and solutions up to 1500cps
• User-friendly and intuitive: easy eye targeting thanks to its blue tip feature, as easy to use as any standard eyedropper
• One drop at a time into the patient’s eye
• Calibrated drops providing a precise dose for a better treatment adherence

For more information, you can visit the dedicated page:

Novelia® will also be shown at differents events in the next months: Interphex, ARVO, FCE Pharma, CPhI China and CPhI Worldwide.

About Nemera

Find Nemera on the web at www.nemera.net

Nemera is a world leader in the design, development and manufacturing of drug delivery solutions. Its expertise covers all five modes of delivery: ophthalmic (multidose, preservative-free eyedroppers), parenteral (auto-injectors, pens, safety devices & implanters), nasal, buccal, auricular (pumps, valves and actuators for sprays), pulmonary (pMDIs, DPIs), dermal and transdermal (airless & atmospheric dispensers).
Nemera provides solutions for the pharmaceutical, biotechnology & generics industries, from full solution development to pure contract manufacturing, through customized solutions.

About Santen

As a specialised company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products and devices. Santen has long been the market leader in Japan for prescription ophthalmic pharmaceuticals and is now a leader in the sector in the EMEA (Europe, Middle East and Africa) region. With scientific knowledge and organisational capabilities nurtured over nearly 130 years, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society in more than 60 countries. For more information, please visit Santen websites www.santen.com (Japan headquarters) and www.santen.eu (EMEA).

[1] Cosopt SmPC, available here: https://www.medicines.org.uk/emc/product/5114/smpc 

[2] EMA Public Statement. Doc. Ref.: EMEA/622721/2009. Last accessed: December 2018

[3] Steven, DW et al. Preservative in glaucoma medication. British Journal of Ophthalmology 2018;102:1497-1503

[4] Renieri G et al. Efficacy and tolerability of preservative-free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients. Journal of Ocular Pharmacology and Therapeutics 2010;26 (6):597–603.

[5] Kaarniranta K et al. Preferences and ease of use of preservative-free IOP-lowering eye drop containers: A comparison of two multi-dose bottles. Clinical Investigation 2018; DOI:10.4172.

[6] Novelia White Paper. Accessible at: http://www.nemera.net/wp-content/uploads/2014/06/WP-Novelia-alternativetofilters-June2015.pdf Last accessed: December 2018

phone +33 4 74 94 06 54
email information@nemera.net
web www.nemera.net
email 20 avenue de la Gare, 38290 – La Verpillière, France
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Pharmapack success points to sizeable growth potential for global drug delivery and packaging in 2019

Paris, 19th March 2019: The drug delivery and healthcare packaging industry is set for significant growth in 2019 as Pharmapack Europe (#pharmapackeu) – a key bellwether of industry health – welcomed a record 410 exhibiting companies and nearly 5,500 attendees from 75 countries. Europe’s biggest pharmaceutical packaging and drug delivery event (Paris Expo, Porte de Versailles, France 6-7 February, 2019) saw a diversification of innovations and new drug delivery solutions, with ‘patient-centricity’ emerging as the central theme throughout this year’s edition.
More info >>


White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

Industry Events

Bio Europe Spring 2019

25-27 March 2019, Messe Wien Exhibition and Congress Center, Vienna

BIO-Europe Spring® is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe®, and continues the tradition of providing life science companies with high caliber partnering opportunities. Featuring EBD Group’s sophisticated, web-based partnering system, partneringONE®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative startups.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement